×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:EXAS

Exact Sciences Stock Forecast, Price & News

$41.13
+1.74 (+4.42%)
(As of 07/1/2022 03:59 PM ET)
Add
Compare
Today's Range
$39.66
$41.50
50-Day Range
$35.61
$62.52
52-Week Range
$35.34
$125.00
Volume
92,549 shs
Average Volume
2.16 million shs
Market Capitalization
$7.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$101.33

Exact Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
146.4% Upside
$101.33 Price Target
Short Interest
Healthy
6.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.54mentions of Exact Sciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$43,581 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.25) to ($3.23) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.36 out of 5 stars

Medical Sector

156th out of 1,428 stocks

Medical Laboratories Industry

3rd out of 32 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

Exact Sciences logo

About Exact Sciences (NASDAQ:EXAS) Stock

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXAS Stock News Headlines

Exact Sciences Corporation
Exact Sciences (NASDAQ:EXAS) Sets New 12-Month Low at $45.37
Expert Ratings for Exact Sciences
EXAS July 8th Options Begin Trading
EXAS June 10th Options Begin Trading
See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXAS
CUSIP
30063P10
Employees
6,500
Year Founded
1995

Company Calendar

Last Earnings
4/26/2022
Today
7/04/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$101.33
High Stock Price Forecast
$155.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+146.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

Net Income
$-595,630,000.00
Pretax Margin
-40.59%

Debt

Sales & Book Value

Annual Sales
$1.77 billion
Book Value
$19.66 per share

Miscellaneous

Free Float
173,482,000
Market Cap
$7.24 billion
Optionable
Optionable
Beta
1.31

Social Links















Exact Sciences Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Exact Sciences stock.
View analyst ratings for Exact Sciences
or view top-rated stocks.

What is Exact Sciences' stock price forecast for 2022?

12 analysts have issued 12 month price targets for Exact Sciences' shares. Their EXAS stock forecasts range from $50.00 to $155.00. On average, they expect Exact Sciences' stock price to reach $101.33 in the next twelve months. This suggests a possible upside of 146.4% from the stock's current price.
View analysts' price targets for Exact Sciences
or view top-rated stocks among Wall Street analysts.

How has Exact Sciences' stock performed in 2022?

Exact Sciences' stock was trading at $77.83 at the beginning of 2022. Since then, EXAS stock has decreased by 47.2% and is now trading at $41.13.
View the best growth stocks for 2022 here
.

When is Exact Sciences' next earnings date?

Exact Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Exact Sciences
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) released its earnings results on Tuesday, April, 26th. The medical research company reported ($1.04) EPS for the quarter, beating analysts' consensus estimates of ($1.12) by $0.08. The medical research company earned $486.57 million during the quarter, compared to the consensus estimate of $461.86 million. Exact Sciences had a negative trailing twelve-month return on equity of 21.82% and a negative net margin of 40.26%. During the same quarter in the previous year, the company posted ($0.18) EPS.
View Exact Sciences' earnings history
.

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences updated its FY 2022 earnings guidance on Tuesday, April, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.99 billion-$2.03 billion, compared to the consensus revenue estimate of $2.01 billion.

Who are Exact Sciences' key executives?

Exact Sciences' management team includes the following people:
  • Mr. Kevin T. Conroy, Chairman of The Board & CEO (Age 56, Pay $2.37M) (LinkedIn Profile)
  • Mr. Jeffrey T. Elliott CFA, Exec. VP, CFO & COO (Age 44, Pay $904.67k)
  • Mr. D. Scott Coward, Chief Legal Officer (Age 57, Pay $847.28k)
  • Mr. Graham P. Lidgard, Emeritus Chief Science Officer (Age 73, Pay $937.04k) (LinkedIn Profile)
  • Mr. Everett V. Cunningham, Chief Commercial Officer (Age 56, Pay $1.01M)
  • Mr. Jake Orville, Gen. Mang. of Pipeline (Age 48, Pay $720.45k)
  • Mr. Gary Frings, Chief Information Officer
  • Dr. Jorge A. Garces Ph.D., Chief Science Officer (Age 50)
  • Ms. Megan Jones, Associate Mang. of Investor Relations
  • Mr. Tim Caprez, Chief Compliance Counsel & VP

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How do I buy shares of Exact Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $41.13.

How much money does Exact Sciences make?

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $7.24 billion and generates $1.77 billion in revenue each year. The medical research company earns $-595,630,000.00 in net income (profit) each year or ($4.32) on an earnings per share basis.

How many employees does Exact Sciences have?

Exact Sciences employs 6,500 workers across the globe.

Does Exact Sciences have any subsidiaries?

The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More

When was Exact Sciences founded?

Exact Sciences was founded in 1995.

How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for Exact Sciences is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.

This page (NASDAQ:EXAS) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.